Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of a physician reviewing glucose trend data with a diabetes patient, reflecting Cirius Therapeutics’ CIR-0602K research and the growing search for new insulin-sensitizing therapies beyond GLP-1 drugs.
Pharma & Biotech

Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity

Cirius Therapeutics is pushing CIR-0602K into the ADA 2026 spotlight. Find out why insulin sensitivity may be diabetes’ next battleground.

Read More
Pharma & Biotech

AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer

Imfinzi has FDA approval with BCG in early high-risk bladder cancer. The next test is adoption, recurrence data and real-world use.

Read More
Representative image of oncologists reviewing advanced gastric cancer imaging in a modern cancer care setting, reflecting Ono Pharmaceutical’s ONO-4578 Phase 2 data and the race to improve first-line treatment for HER2-negative gastric and gastroesophageal junction cancer.
Pharma & Biotech

Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?

Ono’s ONO-4578 improved gastric cancer PFS in Phase 2. The next test is whether EP4 blockade can survive global Phase 3 scrutiny.

Read More
Representative image of oncology researchers reviewing cancer scans and molecular data, reflecting Ranok Therapeutics’ RNK08954 Phase 1a results and the accelerating race to develop KRAS G12D targeted therapies for pancreatic cancer, lung cancer and other advanced solid tumours.
Pharma & Biotech

Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up

KRAS G12D was long seen as nearly untouchable. Ranok’s RNK08954 now has early clinical data, but the pivotal test is still ahead.

Read More
Representative image of a neuromuscular clinic consultation, reflecting Servier’s acquisition of Edgewise Therapeutics’ sevasemten programme and the growing race to develop oral therapies for Becker and Duchenne muscular dystrophy.
Pharma & Biotech

Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?

Servier is buying sevasemten before pivotal muscular dystrophy data. The deal gives Edgewise cash and investors a sharper cardiology story.

Read More
Representative image of a clinician reviewing prostate cancer imaging in a modern nuclear medicine setting, reflecting Convergent Therapeutics’ CONV01-α Phase 2 data and the growing race to develop Actinium-225 radiopharmaceuticals for post-Lu-PSMA metastatic prostate cancer.
Pharma & Biotech

Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?

CONV01-α is targeting the post-Lu-PSMA prostate cancer gap. Convergent now faces the Phase 3 test that will decide its real value.

Read More
Representative image of researchers working in a modern cell therapy laboratory, reflecting T-CURX’s acquisition of Pantherna Therapeutics and the growing race to advance in vivo CAR-T, mRNA delivery and lipid nanoparticle technologies.
Pharma & Biotech

Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing

T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.

Read More
Representative image of an oncologist reviewing lung cancer scans in a modern treatment room, reflecting Amgen’s European approval for Imdylltra and the growing shift toward bispecific antibody therapies for extensive-stage small cell lung cancer.
Pharma & Biotech

Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?

Amgen’s Imdylltra has European approval in relapsed small cell lung cancer. Survival data now face reimbursement and adoption tests.

Read More
Representative image of an oncologist reviewing head and neck cancer scans in a modern clinical setting, reflecting Fulgent Genetics’ FID-007 Phase 2 data and the growing search for new post-PD-1 treatment options in recurrent or metastatic head and neck cancer.
Pharma & Biotech

Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026

Fulgent Genetics has a diagnostics base and a cancer drug signal. FID-007 now faces the tougher Phase 3 test.

Read More
Pharma & Biotech

Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens

Minghui and Qilu’s MHB088C data show durable disease control in mCRPC. Find out why the B7-H3 ADC still faces key clinical tests.

Read More